DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026

PHILADELPHIA, April 3, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased common shares of Ultragenyx during the period from August 3, 2023 through December 26, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Ultragenyx securities during the Class Period may, no later than  April 6, 2026 , seek to be appointed as a lead plaintiff representative of the class.